Promoting Endothelial Function by S-nitrosoglutathione Through the HIF-1α/VEGF Pathway Stimulates Neurorepair and Functional Recovery Following Experimental Stroke in Rats
Overview
Authors
Affiliations
Background: For stroke patients, stimulating neurorepair mechanisms is necessary to reduce morbidity and disability. Our previous studies on brain and spinal cord trauma show that exogenous treatment with the S-nitrosylating agent S-nitrosoglutathione (GSNO) - a nitric oxide and glutathione metabolite of the human body - stimulates neurorepair and aids functional recovery. Using a rat model of cerebral ischemia and reperfusion (IR) in this study, we tested the hypothesis that GSNO invokes the neurorepair process and improves neurobehavioral functions through the angiogenic HIF-1α/VEGF pathway.
Methods: Stroke was induced by middle cerebral artery occlusion for 60 minutes followed by reperfusion in adult male rats. The injured animals were treated with saline (IR group, n=7), GSNO (0.25 mg/kg, GSNO group, n=7), and GSNO plus the HIF-1α inhibitor 2-methoxyestra-diol (2-ME) (0.25 mg/kg GSNO + 5.0 mg/kg 2-ME, GSNO + 2-ME group, n=7). The groups were studied for either 7 or 14 days to determine neurorepair mediators and functional recovery. Brain capillary endothelial cells were used to show that GSNO promotes angiogenesis and that GSNO-mediated induction of VEGF and the stimulation of angiogenesis are dependent on HIF-1α activity.
Results: IR injury increased the expression of neurorepair mediators HIF-1α, VEGF, and PECAM-1 and vessel markers to a limited degree that correlate well with significantly compromised neurobehavioral functions compared with sham animals. GSNO treatment of IR not only remarkably enhanced further the expression of HIF-1α, VEGF, and PECAM-1 but also improved functioning compared with IR. The GSNO group also had a higher degree of vessel density than the IR group. Increased expression of VEGF and the degree of tube formation (angiogenesis) by GSNO were reduced after the inhibition of HIF-1α by 2-ME in an endothelial cell culture model. 2-ME treatment of the GSNO group also blocked not only GSNO's effect of reduced infarct volume, decreased neuronal loss, and enhanced expression of PECAM-1 (P<0.001), but also its improvement of motor and neurological functions (P<0.001).
Conclusion: GSNO stimulates the process of neurorepair, promotes angiogenesis, and aids functional recovery through the HIF-1α-dependent pathway, showing therapeutic and translational promise for stroke.
Advances in Engineered Nanoparticles for the Treatment of Ischemic Stroke by Enhancing Angiogenesis.
Wang G, Li Z, Wang G, Sun Q, Lin P, Wang Q Int J Nanomedicine. 2024; 19:4377-4409.
PMID: 38774029 PMC: 11108071. DOI: 10.2147/IJN.S463333.
Rehabilitation in Animal Models of Stroke.
Khan M Phys Ther Res. 2023; 26(2):39-43.
PMID: 37621571 PMC: 10445120. DOI: 10.1298/ptr.R0022.
Liu J, Luo Q, Ke J, Zhang D, Xu Y, Liao W Oxid Med Cell Longev. 2023; 2023:5157417.
PMID: 36819784 PMC: 9931469. DOI: 10.1155/2023/5157417.
Honokiol improves depression-like behaviors in rats by HIF-1α- VEGF signaling pathway activation.
Fan X, Sun W, Li Y, Tang Q, Li L, Yu X Front Pharmacol. 2022; 13:968124.
PMID: 36091747 PMC: 9453876. DOI: 10.3389/fphar.2022.968124.
Polonikov A, Bocharova I, Azarova I, Klyosova E, Bykanova M, Bushueva O Life (Basel). 2022; 12(4).
PMID: 35455093 PMC: 9032935. DOI: 10.3390/life12040602.